FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene

The FDA approved a treatment for individuals who have amyotrophic lateral sclerosis (ALS) and carry a specific genetic mutation known as the SOD1 gene mutation today. This approval is significant as it provides a treatment option for a small subset of ALS patients who previously did not have any targeted treatment options available. To obtain more information, you can visit the relevant sources on this topic.

We will streamline the regulatory processes so that our clients can utilize

their time and money most efficiently.

Experience the best FDA approval directions and solutions!

If you have any questions about FDA regulation of OTC Drugs and Cosmetics,

Registration and labeling compliance, please CONTACT US.

Office 1-909-493-3276

Email ask@provisionfda.com